ENTAFARMA, UAB - financials and debts

Company age: 25 y. 7 mo.

Update

ENTAFARMA - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 57,224,231 64,331,346 67,215,503 79,877,909 81,361,621 91,294,388 103,323,775 123,629,500
Profit before tax 1,038,268 1,893,772 1,885,074 2,928,366 2,306,151 3,982,896 4,848,258 4,383,130
Net profit 1,002,301 1,803,646 1,813,564 2,756,583 2,219,440 3,600,932 4,646,885 3,660,108
Equity 13,943,780 15,159,192 16,972,756 19,141,105 19,595,840 22,020,302 26,078,952 28,562,589
Liabilities 9,052,263 8,912,097 9,495,416 10,866,622 11,075,229 13,023,571 14,839,355 18,735,830
Non-current assets 739,621 805,740 930,846 2,029,188 2,109,127 3,261,355 3,423,674 1,426,721
Current assets 22,243,980 23,264,201 25,526,269 27,955,314 28,596,863 31,766,073 37,452,999 45,745,921
Total assets 22,983,601 24,069,941 26,457,115 29,984,502 30,705,990 35,027,428 40,876,673 47,172,642
Taxes paid
STI taxes - - - - - 6,045,001 6,810,348 6,813,842
Social insurance contributions - - - - - 870,197 1,019,172 1,079,235
Financial indicators
Revenue change y/y +1.3% +12.4% +4.5% +18.8% +1.9% +12.2% +13.2% +19.7%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 4.4% 7.5% 6.9% 9.2% 7.2% 10.3% 11.4% 7.8%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 7.2% 11.9% 10.7% 14.4% 11.3% 16.4% 17.8% 12.8%
Profit margin Net profit margin. Shows the overall profitability of the company. 1.8% 2.8% 2.7% 3.5% 2.7% 3.9% 4.5% 3.0%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 1.8% 2.9% 2.8% 3.7% 2.8% 4.4% 4.7% 3.5%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.7
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 505,663 484,605 440,998 480,709 475,104 549,690 609,280 705,111

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

Sales revenue

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

ENTAFARMA - Social security debts

From To Debt, €
2024-10-24 2024-11-07 0.49
2024-09-17 2024-09-18 564.94
2024-02-19 2024-02-19 50.89
2022-12-16 2022-12-20 1.76
2022-10-18 2022-10-18 63199.52
2022-07-18 2022-07-19 1245.88
2022-05-18 2022-05-24 250.85
2022-05-17 2022-05-17 179.62

ENTAFARMA - VMI tax arrears

From To Overdue, €
2025-09-19 2025-09-23 15010.71

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
ENTAFARMA, UAB (code 174443844) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €123.63M, up 19.6% year on year and 35.4% over two years, confirming continued expansion. Net profit for 2025 was €3.66M, compared with €4.65M in 2024 and €3.60M in 2023, indicating that profit remained positive but declined from the prior year as the net margin eased to 3.0% from 4.5% in 2024. Total assets increased to €47.17M in 2025 from €40.88M in 2024 and €35.03M in 2023, while equity rose to €28.56M and liabilities to €18.74M. The balance sheet remained equity-backed, with an equity ratio of 60.5% and debt-to-equity of 0.66. Asset turnover was 2.62x, reflecting efficient use of assets in a high-volume trading business. Profitability indicators for 2025 were solid, with ROE at 12.8% and ROA at 7.8%. Revenue per employee reached €706.5K, supporting the view of a productive operating model.